Clinical Trials For My Patients - Bladder Cancer VL

A Study to Improve the Diagnosis of Bladder Cancer - BladderPath Study - Jim Catto & Gary Steinberg

With the oncological safety of TURBT unknown, staging inaccuracies are commonplace, and correct treatment of muscle-invasive bladder cancer is potentially delayed. The BladderPath study is looking at using a multiparametric magnetic resonance imaging (mpMRI) scan to diagnose bladder cancer that has grown into the muscle. Drs. Jim Catto and Gary Steinberg join Dr. Ashish Kamat in a discussion about...

Combining BCG and Intravesical Gemcitabine (GBIG) for Patients with BCG-Relapsing High-Grade NMIBC Cancer A Phase 1/2 Trial- Eugene Pietzak

Eugene Pietzak, MD joins Ashish Kamat, MD MBBS, to discuss an investigator-initiated trial, "Combination BCG and Intravesical Gemcitabine (CBIG) in Patients with BCG Relapsing Non-Muscle Invasive Bladder Cancer" (NCT04179162) that is currently recruiting. Dr. Pietzak explains the rationale for the trial design and the background on the questions this trial seeks to understand, in the combination o...

Phase II Trial for BCG Unresponsive Non-Muscle Invasive Bladder Cancer - Michael Woods

Joining Alicia Morgans, MD, MPH, is Michael Woods, MD, who is the leader of the Alliance trial A031803, a phase II trial studying how well gemcitabine with pembrolizumab works in treating patients with non-muscle invasive bladder cancer (NMIBC) who are unresponsive to bacillus Calmette-Guérin (BCG). This phase II trial studies the effect of adding pembrolizumab to gemcitabine in treating patients...

Genitourinary Cancers Symposium 2021 Trials in Progress TROPiCS-04 - Petros Grivas

Petros Grivas discusses the upcoming ASCO GU 2021 meeting that opens on Thursday, February 11, 2021. Dr. Grivas will be presenting a "Trials in Progress" on the study of sacituzumab govitecan (IMMU-132) in metastatic or locally advanced unresectable urothelial cancer (TROPiCS-04). This is a Phase III, global, multicenter, open-label randomized controlled trial in which approximately 600 subjects w...
email news signup